As more employers make the switch, pressure will mount on these conglomerates to either reform or lose market share. The writing is on the wall. The traditional PBM model is doomed to be a shell ...

EST Psyence Biomedical (PBM) files to sell 3.075M common shares for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

"While we don't test this directly, our work raises the possibility that these rules may be powerful in preventing PBM firms from getting huge market share," she said. Outside of Medicare Part D ...

Unlike a PBM, BSC will pay Evio a flat fee to negotiate ... or lists of therapeutics covered by insurance. This in turn drives market share towards heavily rebated prescription drugs.